FDA Clears Medical Informatics Sickbay Clinical Platform.
M2 PHARMA-June 2, 2015-FDA Clears Medical Informatics Sickbay Clinical Platform
(C)2015 M2 COMMUNICATIONS
US-based healthcare IT company Medical Informatics Corp has received US FDA approval for sale in the US of the company's Sickbay Clinical Platform product
It was also granted three applications, for its Patient Monitor, Patient Alarm Data and Alarm Analytics Dashboard.
The products have FDA 510(k) clearance, which classifies them as Class II medical devices developed for clinical use.
MIC focuses on clinical data transformation to provide actionable information to clinicians for improved quality of care.
At the core of MIC's technology and services is the Sickbay Clinical Platform, which serves as a data collection, aggregation and transformation engine.
Applications run on the Sickbay Platform and provide patient-specific analytics in near real-time to clinicians through a secure web-browser interface.
The Patient Monitoring application re-displays, in near real-time, signals from a patient's bedside monitor and devices in a web-browser for remote viewing in clinical environments.
Because the application is web-based, it allows integration with other third party technologies for the display of physiological data with other relevant patient information.
Alarm Management Dashboards provide up-to-date surveillance of the alarm environment and allow clients to track changes in alarms as improvements are made. Advanced alarm analytics are also calculated and displayed through the web-based interface.
Examples of analytics include time-in-alarm and time-in-alarm-flood.
The Patient Alarm Data application provides intelligent analytics and alarm summaries for individual patients to clinicians.
This information is utilised to establish a patient baseline and set appropriate alarm limits that are tailored for each individual patient.
The Sickbay Clinical Platform and each of the three apps are fully developed and available for purchase, the company said.
((Comments on this story may be sent to firstname.lastname@example.org))